|
1
|
Oosterhuis JW and Looijenga LHJ: Human
germ cell tumours from a developmental perspective. Nat Rev Cancer.
19:522–537. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Drozynska E, Bien E, Polczynska K,
Stefanowicz J, Zalewska-Szewczyk B, Izycka-Swieszewska E,
Ploszynska A, Krawczyk M and Karpinsky G: A need for cautious
interpretation of elevated serum germ cell tumor markers in
children. Review and own experiences. Biomark Med. 9:923–932. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lopes LF, Sonaglio V, Ribeiro KCB,
Schneider DT and de Camargo B: Improvement in the outcome of
children with germ cell tumors. Pediatr Blood Cancer. 50:250–253.
2008. View Article : Google Scholar
|
|
4
|
Veneris JT, Mahajan P and Frazier AL:
Contemporary management of ovarian germ cell tumors and remaining
controversies. Gynecol Oncol. 158:467–475. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Trabert B, Chen J, Devesa SS, Bray F and
McGlynn KA: International patterns and trends in testicular cancer
incidence, overall and by histologic subtype, 1973-2007. Andrology.
3:4–12. 2015. View Article : Google Scholar :
|
|
6
|
Smith HO, Berwick M, Verschraegen CF,
Wiggins C, Lansing L, Muller CY and Qualls CR: Incidence and
survival rates for female malignant germ cell tumors. Obstet
Gynecol. 107:1075–1085. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shaikh F, Murray MJ, Amatruda JF, Coleman
N, Nicholson JC, Hale JP, Pashankar F, Stoneham SJ, Poynter JN,
Olson TA, et al: Paediatric extracranial germ-cell tumours. Lancet
Oncol. 17:e149–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Teilum G: Ovarian Cancer. Gentil F and
Junqueira AC: Springer Berlin Heidelberg; Berlin, Heidelberg: 1968,
Available from: http://link.springer.com/10.1007/978-3-642-87755-1.
|
|
9
|
Yao X, Zhou H, Duan C, Wu X, Li B, Liu H
and Zhang Y: Comprehensive characteristics of pathological subtypes
in testicular germ cell tumor: Gene expression, mutation and
alternative splicing. Front Immunol. 13:10964942023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kobayashi K, Saito T, Kitamura Y,
Nobushita T, Kawasaki T, Hara N and Takahashi K: Oncological
outcomes in patients with stage I testicular seminoma and
nonseminoma: Pathological risk factors for relapse and feasibility
of surveillance after orchiectomy. Diagn Pathol. 8:572013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murray MJ and Nicholson JC: Germ cell
tumours in children and adolescents. Paediatr Child Health.
20:109–116. 2010. View Article : Google Scholar
|
|
12
|
Travis LB, Feldman DR, Fung C, Poynter JN,
Lockley M and Frazier AL: Adolescent and young adult germ cell
tumors: Epidemiology, genomics, treatment, and survivorship. J Clin
Oncol. 42:696–706. 2024. View Article : Google Scholar
|
|
13
|
Fenske AE, Glaesener S, Bokemeyer C,
Thomale J, Dahm-Daphi J, Honecker F and Dartsch DC: Cisplatin
resistance induced in germ cell tumour cells is due to reduced
susceptibility towards cell death but not to altered DNA damage
induction or repair. Cancer Lett. 324:171–178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fichtner A, Bohnenberger H, Elakad O,
Richter A, Lenz C, Oing C, Ströbel P, Kueffer S, Nettersheim D and
Bremmer F: Proteomic profiling of cisplatin-resistant and
cisplatin-sensitive germ cell tumour cell lines using quantitative
mass spectrometry. World J Urol. 40:373–383. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Selfe J, Goddard NC, McIntyre A, Taylor
KR, Renshaw J, Popov SD, Thway K, Summersgill B, Huddart RA,
Gilbert DC and Shipley JM: IGF1R signalling in testicular germ cell
tumour cells impacts on cell survival and acquired cisplatin
resistance. J Pathol. 244:242–253. 2018. View Article : Google Scholar :
|
|
16
|
Galvez-Carvajal L, Sanchez-Muñoz A,
Ribelles N, Saez M, Baena J, Ruiz S, Ithurbisquy C and Alba E:
Targeted treatment approaches in refractory germ cell tumors. Crit
Rev Oncol Hematol. 143:130–138. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lobo J, Guimarães-Teixeira C, Barros-Silva
D, Miranda-Gonçalves V, Camilo V, Guimarães R, Cantante M, Braga I,
Maurício J, Oing C, et al: Efficacy of HDAC inhibitors belinostat
and panobinostat against cisplatin-sensitive and
cisplatin-resistant testicular germ cell tumors. Cancers (Basel).
12:29032020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wermann H, Stoop H, Gillis AJ, Honecker F,
van Gurp RJ, Ammerpohl O, Richter J, Oosterhuis JW, Bokemeyer C and
Looijenga LH: Global DNA methylation in fetal human germ cells and
germ cell tumours: Association with differentiation and cisplatin
resistance. J Pathol. 221:433–442. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Juliachs M, Muñoz C, Moutinho CA, Vidal A,
Condom E, Esteller M, Graupera M, Casanovas O, Germà JR, Villanueva
A and Viñals F: The PDGFRβ-AKT pathway contributes to CDDP-acquired
resistance in testicular germ cell tumors. Clin Cancer Res.
20:658–667. 2014. View Article : Google Scholar
|
|
20
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
|
|
21
|
Cardoso I, Rosa M, Moreno D, Tufi L, Ramos
L, Pereira L, Silva L, Galvão JMS, Tosi IC, Lengert AVH, et al:
Cisplatin-resistant germ cell tumor models: An exploration of the
epithelial-mesenchymal transition regulator SLUG. Mol Med Rep.
30:2282024. View Article : Google Scholar
|
|
22
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thiery JP, Acloque H, Huang RYJ and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim K, Lu Z and Hay ED: Direct evidence
for a role of β-catenin/LEF-1 signaling pathway in induction of
EMT. Cell Biol Int. 26:463–476. 2002. View Article : Google Scholar
|
|
25
|
Nawshad A, LaGamba D, Polad A and Hay ED:
Transforming growth factor-β signaling during
epithelial-mesenchymal transformation: Implications for
embryogenesis and tumor metastasis. Cells Tissues Organs.
179:11–23. 2005. View Article : Google Scholar
|
|
26
|
Medici D, Hay ED and Olsen BR: Snail and
slug promote epithelial-Mesenchymal Transition through
β-catenin-T-cell Factor-4-dependent expression of transforming
growth factor-β3. Mol Biol Cell. 19:4875–4887. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grasset EM, Dunworth M, Sharma G, Loth M,
Tandurella J, Cimino-Mathews A, Gentz M, Bracht S, Haynes M, Fertig
EJ and Ewald AJ: Triple-negative breast cancer metastasis involves
complex epithelial-mesenchymal transition dynamics and requires
vimentin. Sci Transl Med. 14:eabn75712022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ugur D, Gungul TB, Yucel S, Ozcivici E,
Yalcin-Ozuysal O and Mese G: Connexin 32 overexpression increases
proliferation, reduces gap junctional intercellular communication,
motility and epithelial-to-mesenchymal transition in Hs578T breast
cancer cells. J Cell Commun Signal. 16:361–376. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zvrko E, Vuckovic L and Radunovic M:
Prognostic significance of a panel of two biomarkers (E-cadherin
and CD105) in laryngeal cancer. Polish J Pathol. 74:225–231. 2023.
View Article : Google Scholar
|
|
30
|
Jiang JX and Gu S: Gap junction- and
hemichannel-independent actions of connexins. Biochim Biophys Acta.
1711:208–214. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Y, Acosta FM and Jiang JX: Gap
Junctions or Hemichannel-dependent and independent roles of
connexins in fibrosis, epithelial-mesenchymal transitions, and
wound healing. Biomolecules. 13:17962023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Trelstad RL: The extracellular matrix in
development and regeneration. An interview with Elizabeth D. Hay.
Int J Dev Biol. 48:687–694. 2004. View Article : Google Scholar
|
|
33
|
Debnath P, Huirem RS, Dutta P and
Palchaudhuri S: Epithelial-mesenchymal transition and its
transcription factors. Biosci Rep. 42:BSR202117542022. View Article : Google Scholar
|
|
34
|
Piek E, Moustakas A, Kurisaki A, Heldin CH
and ten Dijke P: TGF-β type I receptor/ALK-5 and Smad proteins
mediate epithelial to mesenchymal transdifferentiation in NMuMG
breast epithelial cells. J Cell Sci. 112:4557–4568. 1999.
View Article : Google Scholar
|
|
35
|
Guo X, Yi H, Li TC, Wang Y, Wang H and
Chen X: Role of vascular endothelial growth factor (VEGF) in human
embryo implantation: Clinical implications. Biomolecules.
11:2532021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Batarfi WA, Mohd Yunus MH and Hamid AA:
The Effect of Hydroxytyrosol in Type II Epithelial-Mesenchymal
transition in human skin wound healing. Molecules. 28:26522023.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Marconi GD, Fonticoli L, Rajan TS,
Pierdomenico SD, Trubiani O, Pizzicannella J and Diomede F:
Epithelial-mesenchymal transition (EMT): The Type-2 EMT in wound
healing, tissue regeneration and organ fibrosis. Cells.
10:15872021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tennakoon A, Izawa T, Kuwamura M and
Yamate J: Pathogenesis of type 2 epithelial to mesenchymal
transition (EMT) in renal and hepatic fibrosis. J Clin Med.
5:42015. View Article : Google Scholar
|
|
39
|
Linsdell P: Cystic fibrosis transmembrane
conductance regulator (CFTR): Making an ion channel out of an
active transporter structure. Channels. 12:284–290. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cui H, Huang J, Lei Y, Chen Q, Hu Z, Niu
J, Wei R, Yang K, Li H, Lu T, et al: Design and synthesis of dual
inhibitors targeting snail and histone deacetylase for the
treatment of solid tumour cancer. Eur J Med Chem. 229:1140822022.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hotz B, Arndt M, Dullat S, Bhargava S,
Buhr HJ and Hotz HG: Epithelial to mesenchymal transition:
Expression of the regulators snail, slug, and twist in pancreatic
cancer. Clin Cancer Res. 13:4769–4776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zivotic M, Kovacevic S, Nikolic G,
Mioljevic A, Filipovic I, Djordjevic M, Jovicic V, Topalovic N,
Ilic K, Radojevic Skodric S, et al: SLUG and SNAIL as potential
immunohistochemical biomarkers for renal cancer staging and
survival. Int J Mol Sci. 24:122452023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ashrafizadeh M, Zarrabi A, Hushmandi K,
Kalantari M, Mohammadinejad R, Javaheri T and Sethi G: Association
of the epithelial-mesenchymal transition (EMT) with Cisplatin
resistance. Int J Mol Sci. 21:40022020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Haslehurst AM, Koti M, Dharsee M, Nuin P,
Evans K, Geraci J, Chen J, Li J, Weberpals J, Davey S, et al: EMT
transcription factors snail and slug directly contribute to
cisplatin resistance in ovarian cancer. BMC Cancer. 12:912012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cooper S and Pera MF: Vitronectin
production by human yolk sac carcinoma cells resembling parietal
endoderm. Development. 104:565–574. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ruoslahti E, Jalanko H, Comings DE,
Neville AM and Raghavan D: Fibronectin from human germ-cell tumors
resembles amniotic fluid fibronectin. Int J Cancer. 27:763–767.
1981. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tauber S, Jais A, Jeitler M, Haider S,
Husa J, Lindroos J, Knöfler M, Mayerhofer M, Pehamberger H, Wagner
O and Bilban M: Transcriptome analysis of human cancer reveals a
functional role of Heme Oxygenase-1 in tumor cell adhesion. Mol
Cancer. 9:2002010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Borszéková Pulzová LB, Roška J, Kalman M,
Kliment J, Slávik P, Smolková B, Goffa E, Jurkovičová D, Kulcsár Ľ,
Lešková K, et al: Screening for the key proteins associated with
rete testis invasion in clinical stage I seminoma via label-free
quantitative mass spectrometry. Cancers (Basel). 13:55732021.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sherman-Baust CA, Weeraratna AT, Rangel
LBA, Pizer ES, Cho KR, Schwartz DR, Shock T and Morin PJ:
Remodeling of the extracellular matrix through overexpression of
collagen VI contributes to cisplatin resistance in ovarian cancer
cells. Cancer Cell. 3:377–386. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Skowron MA, Eul K, Stephan A, Ludwig GF,
Wakileh GA, Bister A, Söhngen C, Raba K, Petzsch P, Poschmann G, et
al: Profiling the 3D interaction between germ cell tumors and
microenvironmental cells at the transcriptome and secretome level.
Mol Oncol. 16:3107–3127. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Henke E, Nandigama R and Ergün S:
Extracellular matrix in the tumor microenvironment and its impact
on cancer therapy. Front Mol Biosci. 6:1602020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sun L, Guo S, Xie Y and Yao Y: The
characteristics and the multiple functions of integrin β1 in human
cancers. J Transl Med. 21:7872023. View Article : Google Scholar
|
|
53
|
Butler TM, Elustondo PA, Hannigan GE and
MacPhee DJ: Integrin-linked kinase can facilitate syncytialization
and hormonal differentiation of the human trophoblast-derived BeWo
cell line. Reprod Biol Endocrinol. 7:512009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sánchez-Tilló E, Liu Y, de Barrios O,
Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A
and Postigo A: EMT-activating transcription factors in cancer:
Beyond EMT and tumor invasiveness. Cell Mol Life Sci. 69:3429–3456.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ng YH, Zhu H and Leung PCK: Twist
regulates cadherin-mediated differentiation and fusion of human
trophoblastic cells. J Clin Endocrinol Metab. 96:3881–3890. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhang C, Song Y, Yin Y, Hou H and Ge Z:
Twist-1 stimulates the malignant behaviors of Hydatidiform mole via
the PI3K/AKT pathway. Discov Med. 36:2862024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bahar E, Kim JY, Kim HS and Yoon H:
Establishment of acquired cisplatin resistance in ovarian cancer
cell lines characterized by enriched metastatic properties with
increased twist expression. Int J Mol Sci. 21:76132020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
DaSilva-Arnold SC, Kuo CY, Davra V,
Remache Y, Kim PCW, Fisher JP, Zamudio S, Al-Khan A, Birge RB and
Illsley NP: ZEB2, a master regulator of the epithelial-mesenchymal
transition, mediates trophoblast differentiation. Mol Hum Reprod.
25:61–75. 2019. View Article : Google Scholar
|
|
59
|
Teveroni E, Di Nicuolo F, Vergani E,
Bianchetti G, Bruno C, Maulucci G, De Spirito M, Cenci T, Pierconti
F, Gulino G, et al: PTTG1/ZEB1 axis regulates E-cadherin expression
in human seminoma. Cancers (Basel). 14:48762022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tian Q, Xue Y, Zheng W, Sun R, Ji W, Wang
X and An R: Overexpression of hypoxia-inducible factor 1α induces
migration and invasion through Notch signaling. Int J Oncol.
47:728–738. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Xu Y, Ren B and Wang M: HIF-1α contributes
to metastasis in choriocarcinoma by regulating DEC1 expression.
Clin Transl Oncol. 25:1641–1649. 2022. View Article : Google Scholar
|
|
62
|
Iwaki T, Yamamoto K, Matsuura T, Sugimura
M, Kobayashi T and Kanayama N: Alteration of Integrins under
hypoxic stress in early placenta and choriocarcinoma cell line
BeWo. Gynecol Obstet Invest. 57:196–203. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Xue Y, Sun R, Zheng W, Yang L and An R:
Forskolin promotes vasculogenic mimicry and invasion via
Notch-1-activated epithelial-to-mesenchymal transition in
syncytiolization of trophoblast cells in choriocarcinoma. Int J
Oncol. 56:1129–1139. 2020.PubMed/NCBI
|
|
64
|
Wu YC, Ling TY, Lu SH, Kuo HC, Ho HN, Yeh
SD, Shen CN and Huang YH: Chemotherapeutic sensitivity of
testicular germ cell tumors under hypoxic conditions is negatively
regulated by SENP1-controlled Sumoylation of OCT4. Cancer Res.
72:4963–4973. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Koch S, Mayer F, Honecker F, Schittenhelm
M and Bokemeyer C: Efficacy of cytotoxic agents used in the
treatment of testicular germ cell tumours under normoxic and
hypoxic conditions in vitro. Br J Cancer. 89:2133–2139. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Liu Z, Fang B, Cao J, Zhou Q, Zhu F, Fan
L, Xue L, Huang C and Bo H: LINC00313 regulates the metastasis of
testicular germ cell tumors through epithelial-mesenchyme
transition and immune pathways. Bioengineered. 13:12141–12155.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lengert AVH, Pereira LDNB, Cabral ERM,
Gomes INF, Jesus LM, Gonçalves MFS, Rocha AOD, Tassinari TA, Silva
LSD, Laus AC, et al: Potential new therapeutic approaches for
cisplatin-resistant testicular germ cell tumors. Front Biosci
(Landmark Ed). 27:2452022. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Sun C, Zhang K, Ni C, Wan J, Duan X, Lou
X, Yao X, Li X, Wang M, Gu Z, et al: Transgelin promotes lung
cancer progression via activation of cancer-associated fibroblasts
with enhanced IL-6 release. Oncogenesis. 12:182023. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhong W, Hou H, Liu T, Su S, Xi X, Liao Y,
Xie R, Jin G, Liu X, Zhu L, et al: Cartilage Oligomeric Matrix
Protein promotes epithelial-mesenchymal transition by interacting
with Transgelin in colorectal cancer. Theranostics. 10:8790–8806.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Oshi M, Tokumaru Y, Mukhopadhyay S, Yan L,
Matsuyama R, Endo I and Takabe K: Annexin A1 expression is
associated with Epithelial-Mesenchymal transition (EMT), cell
proliferation, prognosis, and drug response in pancreatic cancer.
Cells. 10:6532021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Cortes-Dericks L, Froment L, Boesch R,
Schmid RA and Karoubi G: Cisplatin-resistant cells in malignant
pleural mesothelioma cell lines show ALD(Hhigh)CD44(+) phenotype
and sphere-forming capacity. BMC Cancer. 14:3042014. View Article : Google Scholar
|
|
72
|
Liu YP, Yang CJ, Huang MS, Yeh CT, Wu ATH,
Lee YC, Lai TC, Lee CH, Hsiao YW, Lu J, et al: Cisplatin selects
for multidrug-resistant CD133+ cells in lung adenocarcinoma by
activating notch signaling. Cancer Res. 73:406–416. 2013.
View Article : Google Scholar
|
|
73
|
Schmidtova S, Kalavska K, Gercakova K,
Cierna Z, Miklikova S, Smolkova B, Buocikova V, Miskovska V,
Durinikova E, Burikova M, et al: Disulfiram overcomes cisplatin
resistance in human embryonal carcinoma cells. Cancers (Basel).
11:12242019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Schmidtova S, Dorssers LCJ, Kalavska K,
Gillis AJM, Oosterhuis JW, Stoop H, Miklikova S, Kozovska Z,
Burikova M, Gercakova K, et al: Napabucasin overcomes cisplatin
resistance in ovarian germ cell tumor-derived cell line by
inhibiting cancer stemness. Cancer Cell Int. 20:3642020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Roška J, Wachsmannová L, Hurbanová L,
Šestáková Z, Mueller T, Jurkovičová D and Chovanec M: Differential
gene expression in cisplatin-resistant and -sensitive testicular
germ cell tumor cell lines. Oncotarget. 11:4735–4753. 2020.
View Article : Google Scholar
|
|
76
|
Makino S, Takahashi H, Okuzaki D, Miyoshi
N, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Mizushima T, Mori M
and Doki Y: DCLK1 integrates induction of TRIB3, EMT, drug
resistance and poor prognosis in colorectal cancer. Carcinogenesis.
41:303–312. 2020. View Article : Google Scholar
|
|
77
|
Chen X, Zhang Y, Zhang P, Wei M, Tian T,
Guan Y, Han C, Wei W and Ma Y: IGFBP2 drives epithelial-mesenchymal
transition in hepatocellular carcinoma via activating the
Wnt/β-catenin pathway. Infect Agent Cancer. 18:732023. View Article : Google Scholar
|
|
78
|
Liu S, Sun J, Cai B, Xi X, Yang L, Zhang
Z, Feng Y and Sun Y: NANOG regulates epithelial-mesenchymal
transition and chemoresistance through activation of the STAT3
pathway in epithelial ovarian cancer. Tumor Biol. 37:9671–9680.
2016. View Article : Google Scholar
|
|
79
|
Bu X, Liu Y, Wang L, Yan Z, Xin G and Su
W: Oct4 promoted proliferation, migration, invasion, and
epithelial-mesenchymal transition (EMT) in colon cancer cells by
activating the SCF/c-Kit signaling pathway. Cell Cycle. 22:291–302.
2023. View Article : Google Scholar :
|
|
80
|
Fukusumi T, Guo T, Ren S, Haft S, Liu C,
Sakai A, Ando M, Saito Y, Sadat S and Califano JA: Reciprocal
activation of HEY1 and NOTCH4 under SOX2 control promotes EMT in
head and neck squamous cell carcinoma. Int J Oncol. 58:226–237.
2020. View Article : Google Scholar
|
|
81
|
Abada PB and Howell SB: Cisplatin induces
resistance by triggering differentiation of testicular embryonal
carcinoma cells. PLoS One. 9:e874442014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Honecker F, Kersemaekers AF, Molier M, van
Weeren PC, Stoop H, de Krijger RR, Wolffenbuttel KP, Oosterhuis W,
Bokemeyer C and Looijenga LH: Involvement of E-cadherin and
β-catenin in germ cell tumours and in normal male fetal germ cell
development. J Pathol. 204:167–174. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Young JC, Kerr G, Micati D, Nielsen JE,
Rajpert-De Meyts E, Abud HE and Loveland KL: WNT signalling in the
normal human adult testis and in male germ cell neoplasms. Hum
Reprod. 35:1991–2003. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Schmidtova S, Kalavska K, Liskova V, Plava
J, Miklikova S, Kucerova L, Matuskova M, Rojikova L, Cierna Z,
Rogozea A, et al: Targeting of deregulated Wnt/β-catenin signaling
by PRI-724 and LGK974 inhibitors in germ cell tumor cell lines. Int
J Mol Sci. 22:42632021. View Article : Google Scholar
|
|
85
|
Serrano-Gomez SJ, Maziveyi M and Alahari
SK: Regulation of epithelial-mesenchymal transition through
epigenetic and post-translational modifications. Mol Cancer.
15:182016. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Olaizola P, Lee-Law PY, Fernandez-Barrena
MG, Alvarez L, Cadamuro M, Azkargorta M, O'Rourke CJ,
Caballero-Camino FJ, Olaizola I, Macias RIR, et al: Targeting
NAE1-mediated protein hyper-NEDDylation halts
cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in
experimental models. J Hepatol. 77:177–190. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Nawrocki ST, Kelly KR, Smith PG, Espitia
CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M,
Berger A and Carew JS: Disrupting protein NEDDylation with MLN4924
is a novel strategy to target cisplatin resistance in ovarian
cancer. Clin Cancer Res. 19:3577–3590. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Funke K, Einsfelder U, Hansen A, Arévalo
L, Schneider S, Nettersheim D, Stein V and Schorle H: Genome-scale
CRISPR screen reveals neddylation to contribute to cisplatin
resistance of testicular germ cell tumours. Br J Cancer.
128:2270–2282. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zhao Y, Morgan MA and Sun Y: Targeting
Neddylation pathways to inactivate Cullin-RING ligases for
anticancer therapy. Antioxid Redox Signal. 21:2383–2400. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Miranda-Gonçalves V, Lobo J,
Guimarães-Teixeira C, Barros-Silva D, Guimarães R, Cantante M,
Braga I, Maurício J, Oing C, Honecker F, et al: The component of
the m6A writer complex VIRMA is implicated in aggressive
tumor phenotype, DNA damage response and cisplatin resistance in
germ cell tumors. J Exp Clin Cancer Res. 40:2682021. View Article : Google Scholar
|
|
91
|
Port M, Glaesener S, Ruf C, Riecke A,
Bokemeyer C, Meineke V, Honecker F and Abend M: Micro-RNA
expression in cisplatin resistant germ cell tumor cell lines. Mol
Cancer. 10:522011. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Skowron MA, Vermeulen M, Winkelhausen A,
Becker TK, Bremmer F, Petzsch P, Schönberger S, Calaminus G, Köhrer
K, Albers P and Nettersheim D: CDK4/6 inhibition presents as a
therapeutic option for paediatric and adult germ cell tumours and
induces cell cycle arrest and apoptosis via canonical and
non-canonical mechanisms. Br J Cancer. 123:378–391. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Noel EE, Yeste-Velasco M, Mao X, Perry J,
Kudahetti SC, Li NF, Sharp S, Chaplin T, Xue L, McIntyre A, et al:
The association of CCND1 overexpression and cisplatin resistance in
testicular germ cell tumors and other cancers. Am J Pathol.
176:2607–2615. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Moyret-Lalle C, Prodhomme MK, Burlet D,
Kashiwagi A, Petrilli V, Puisieux A, Seimiya H and Tissier A: Role
of EMT in the DNA damage response, double-strand break repair
pathway choice and its implications in cancer treatment. Cancer
Sci. 113:2214–2223. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Scheel C and Weinberg RA: Cancer stem
cells and epithelial-mesenchymal transition: Concepts and molecular
links. Semin Cancer Biol. 22:396–403. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Assani G and Zhou Y: Effect of modulation
of epithelial-mesenchymal transition regulators Snail1 and Snail2
on cancer cell radiosensitivity by targeting of the cell cycle,
cell apoptosis and cell migration/invasion. Oncol Lett. 17:23–30.
2019.PubMed/NCBI
|
|
97
|
Damjanov I, Clark RK and Andrews PW:
Cytoskeleton of human embryonal carcinoma cells. Cell Differ.
15:133–139. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Tian Q, Xue Y, Zheng W, Sun R, Ji W, Wang
X and An R: Overexpression of hypoxia-inducible factor 1α induces
migration and invasion through Notch signaling. Int J Oncol.
47:728–738. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Micati DJ, Hime GR, McLaughlin EA, Abud HE
and Loveland KL: Differential expression profiles of conserved
Snail transcription factors in the mouse testis. Andrology.
6:362–373. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Micati DJ, Radhakrishnan K, Young JC,
Rajpert-De Meyts E, Hime GR, Abud HE and Loveland KL: Snail factors
in testicular germ cell tumours and their regulation by the BMP4
signalling pathway. Andrology. 8:1456–14570. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Moody SE, Perez D, Pan TC, Sarkisian CJ,
Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD and
Chodosh LA: The transcriptional repressor Snail promotes mammary
tumor recurrence. Cancer Cell. 8:197–209. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Dominis M: The generation and in vivo
differentiation of murine embryonal stem cells genetically null for
either N-cadherin or N-and P-cadherin [Internet]. Article in the
International Journal of Developmental Biology. 1999, Available
from: https://www.researchgate.net/publication/12607650.
|
|
103
|
Sasaki T, Forsberg E, Bloch W, Addicks K,
Fässler R and Timpl R: Deficiency of β1 Integrins in teratoma
interferes with basement membrane assembly and Laminin-1
expression. Exp Cell Res. 238:70–81. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Rusciano D, Lorenzoni P and Burger MM: The
role of both specific cellular adhesion and growth promotion in
liver colonization by F9 embryonal carcinoma cells. Int J Cancer.
48:450–456. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Rossin R, Berndorff D, Friebe M,
Dinkelborg LM and Welch MJ: Small-animal PET of tumor angiogenesis
using a 76Br-labeled human recombinant antibody fragment to the
ED-B domain of Fibronectin. J Nuclear Med. 48:1172–1179. 2007.
View Article : Google Scholar
|
|
106
|
Andrews PA, Jones JA, Varki NM and Howell
SB: Rapid emergence of acquired cis-Diamminedichloroplatinum(II)
resistance in an in vivo model of human ovarian carcinoma. Cancer
Commun. 2:93–100. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Caffrey PB and Frenkel GD: Prevention of
carboplatin-induced resistance in human ovarian tumor xenografts by
selenite. Anticancer Res. 33:4249–4254. 2013.PubMed/NCBI
|
|
108
|
Caffrey PB, Frenkel GD, Mcandrew KL and
Marks K: A model of the development of cisplatin resistance in
human small cell lung cancer Xenografts. In Vivo. 30:745–750. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Jones C, Dziadowicz S, Suite S, Eby A,
Chen WC, Hu G and Hazlehurst LA: Emergence of resistance to MTI-101
selects for a MET genotype and phenotype in EGFR driven PC-9 and
PTEN deleted H446 lung cancer cell lines. Cancers (Basel).
14:30622022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Fuchs J, Wenderoth M, von Schweinitz D,
Haindl J and Leuschner I: Comparative activity of cisplatin,
ifosfamide, doxorubicin, carboplatin, and etoposide in
heterotransplanted hepatoblastoma. Cancer. 83:2400–2407. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Warmann S, Hunger M, Teichmann B, Flemming
P, Gratz KF and Fuchs J: The role of the MDR1 gene in the
development of multidrug resistance in human hepatoblastoma.
Cancer. 95:1795–1801. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Rendón-Barrón MJ, Pérez-Arteaga E,
Delgado-Waldo I, Coronel-Hernández J, Pérez-Plasencia C,
Rodríguez-Izquierdo F, Linares R, González-Esquinca AR,
Álvarez-González I, Madrigal-Bujaidar E and Jacobo-Herrera NJ:
Laherradurin inhibits tumor growth in an Azoxymethane/dextran
sulfate sodium colorectal cancer model in vivo. Cancers (Basel).
16:5732024. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Venkatasamy A, Guerin E, Blanchet A,
Orvain C, Devignot V, Jung M, Jung AC, Chenard MP, Romain B,
Gaiddon C and Mellitzer G: Ultrasound and transcriptomics identify
a differential impact of cisplatin and histone deacetylation on
tumor structure and microenvironment in a Patient-derived in vivo
model of gastric cancer. Pharmaceutics. 13:14852021. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Satta T, Isobe K, Yamauchi M, Nakashima I,
Akiyama S, Itou K, Watanabe T and Takagi H: Establishment of drug
resistance in human gastric and colon carcinoma xenograft lines.
Jpn J Cancer Res. 82:593–598. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Rocha CRR, Garcia CCM, Vieira DB, Quinet
A, de Andrade-Lima LC, Munford V, Belizário JE and Menck CF:
Glutathione depletion sensitizes cisplatin- and
temozolomide-resistant glioma cells in vitro and in vivo. Cell
Death Dis. 5:e1505. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Gumbarewicz E, Tylżanowski P, Łuszczki J,
Kałafut J, Czerwonka A, Szumiło J, Wawruszak A, Kupisz K, Polberg
K, Smok-Kalwat J and Stepulak A: Differential molecular response of
larynx cancer cell lines to combined VPA/CDDP treatment. Am J
Cancer Res. 11:2821–2837. 2021.PubMed/NCBI
|
|
117
|
Albany C, Hever-Jardine MP, von Herrmann
KM, Yim CY, Tam J, Warzecha JM, Shin L, Bock SE, Curran BS,
Chaudhry AS, et al: Refractory testicular germ cell tumors are
highly sensitive to the second generation DNA methylation inhibitor
guadecitabine. Oncotarget. 8:2949–2959. 2017. View Article : Google Scholar :
|
|
118
|
Jørgensen A, Blomberg Jensen M, Nielsen
JE, Juul A and Rajpert-De Meyts E: Influence of vitamin D on
cisplatin sensitivity in testicular germ cell cancer-derived cell
lines and in a NTera2 xenograft model. J Steroid Biochem Mol Biol.
136:238–246. 2013. View Article : Google Scholar
|
|
119
|
de Vries G, Rosas-Plaza X, Meersma GJ,
Leeuwenburgh VC, Kok K, Suurmeijer AJH, van Vugt MATM, Gietema JA
and de Jong S: Establishment and characterisation of testicular
cancer patient-derived xenograft models for preclinical evaluation
of novel therapeutic strategies. Sci Rep. 10:189382020. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Juliachs M, Castillo-Ávila W, Vidal A,
Piulats JM, Garcia del Muro X, Condom E, Hernández-Losa J, Teixidó
C, Pandiella A, Graupera M, et al: ErbBs inhibition by lapatinib
blocks tumor growth in an orthotopic model of human testicular germ
cell tumor. Int J Cancer. 133:235–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Kitayama S, Ikeda K, Sato W, Takeshita H,
Kawakami S, Inoue S and Horie K: Testis-expressed gene 11 inhibits
cisplatin-induced DNA damage and contributes to chemoresistance in
testicular germ cell tumor. Sci Rep. 12:184232022. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Sakurai Y, Ichinoe M, Yoshida K, Nakazato
Y, Saito S, Satoh M, Nakada N, Sanoyama I, Umezawa A, Numata Y, et
al: Inactivation of REV7 enhances chemosensitivity and overcomes
acquired chemoresistance in testicular germ cell tumors. Cancer
Lett. 489:100–110. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Olayioye MA, Neve RM, Lane HA and Hynes
NE: The ErbB signaling network: Receptor heterodimerization in
development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Yonesaka K, Zejnullahu K, Okamoto I, Satoh
T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda
M, et al: Activation of ERBB2 signaling causes resistance to the
EGFR-directed therapeutic antibody cetuximab. Sci Transl Med.
3:99ra862011. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Jonckheere S, Adams J, De Groote D,
Campbell K, Berx G and Goossens S: Epithelial-mesenchymal
transition (EMT) as a therapeutic target. Cells Tissues Organs.
211:157–182. 2022. View Article : Google Scholar
|
|
126
|
Zhao HB, Wang C, Li RX, Tang CL, Li MQ, Du
MR, Hou XF and Li DJ: E-Cadherin, as a negative regulator of
invasive behavior of human trophoblast cells, is Down-regulated by
cyclosporin A via epidermal growth Factor/extracellular
Signal-regulated protein kinase signaling pathway1. Biol Reprod.
83:370–376. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Hsien Lai S, Zervoudakis G, Chou J, Gurney
ME and Quesnelle KM: PDE4 subtypes in cancer. Oncogene.
39:3791–3802. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Huang Y, Zheng Y, Wang Q and Qi C:
Rolipram suppresses migration and invasion of human choriocarcinoma
cells by inhibiting phosphodiesterase 4-mediated
epithelial-mesenchymal transition. J Biochem Mol Toxicol.
37:e233632023. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Dyshlovoy SA, Venz S, Hauschild J,
Tabakmakher KM, Otte K, Madanchi R, Walther R, Guzii AG, Makarieva
TN, Shubina LK, et al: Anti-migratory activity of marine alkaloid
monanchocidin A-proteomics-based discovery and confirmation.
Proteomics. 16:1590–1603. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Ooki A, Satoh T, Muro K, Takashima A,
Kadowaki S, Sakai D, Ichimura T, Mitani S, Kudo T, Chin K, et al: A
phase 1b study of andecaliximab in combination with S-1 plus
platinum in Japanese patients with gastric adenocarcinoma. Sci Rep.
12:11002022. View Article : Google Scholar
|
|
131
|
Bendell J, Sharma S, Patel MR, Windsor KS,
Wainberg ZA, Gordon M, Chaves J, Berlin J, Brachmann CB,
Zavodovskaya M, et al: Safety and efficacy of andecaliximab
(GS-5745) plus gemcitabine and nab-paclitaxel in patients with
advanced pancreatic adenocarcinoma: Results from a phase I study.
Oncologist. 25:954–962. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Yoshikawa AK, Yamaguchi K, Muro K,
Takashima A, Ichimura T, Sakai D, Kadowaki S, Chin K, Kudo T,
Mitani S, et al: Safety and tolerability of andecaliximab as
monotherapy and in combination with an anti-PD-1 antibody in
Japanese patients with gastric or gastroesophageal junction
adenocarcinoma: A phase 1b study. J Immunother Cancer.
10:e0035182022. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Shah MA, Cunningham D, Metges JP, Van
Cutsem E, Wainberg Z, Elboudwarej E, Lin KW, Turner S, Zavodovskaya
M, Inzunza D, et al: Randomized, open-label, phase 2 study of
andecaliximab plus nivolumab versus nivolumab alone in advanced
gastric cancer identifies biomarkers associated with survival. J
Immunother Cancer. 9:e0035802021. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Coleman N, Stephen B, Fu S, Karp D,
Subbiah V, Ahnert JR, Piha-Paul SA, Wright J, Fessahaye SN, Ouyang
F, et al: Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in
combination with Ziv-aflibercept in patients with advanced solid
tumors. Cancer Med. 13:e68772024. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Ferrarotto R, Swiecicki PL, Zandberg DP,
Baiocchi RA, Wesolowski R, Rodriguez CP, McKean M, Kang H, Monga V,
Nath R, et al: PRT543, a protein arginine methyltransferase 5
inhibitor, in patients with advanced adenoid cystic carcinoma: An
open-label, phase I dose-expansion study. Oral Oncol.
149:1066342024. View Article : Google Scholar
|
|
136
|
Xi M, Guo S, Bayin C, Peng L, Chuffart F,
Bourova-Flin E, Rousseaux S, Khochbin S, Mi JQ and Wang J:
Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute
lymphoblastic leukemia. Front Med. 16:442–458. 2022. View Article : Google Scholar
|
|
137
|
Falchook GS, Wheler JJ, Naing A, Jackson
EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, et al:
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with
antiangiogenic therapy: A phase I trial of bortezomib plus
bevacizumab. Oncotarget. 5:10280–10292. 2014. View Article : Google Scholar : PubMed/NCBI
|
![Graphical representation of EMP
markers, cisplatin resistance and potential inhibitors across GCT
histologies. This figure illustrates the histologies studied both
in vivo and in vitro, including those related to
cisplatin resistance and the status of potential inhibitors for
targeted therapy. Red circles indicate association with cisplatin
resistance. Created in BioRender. Pinto, M. (2025) https://BioRender.com/x70i558.EMP,
epithelial-mesenchymal plasticity; GCT, germ cell tumor; CCND1,
cyclin D1; ErbB, ErbB family; CD133, prominin-1; ALDH3A1, aldehyde
dehydrogenase 3 family member A1; ABCG2, ATP binding cassette
subfamily G member 2; TRIB3, Tribbles pseudokinase 3; IGFBP2,
insulin-like growth factor binding protein 2; NANOG, homeobox
protein NANOG; POU5F1, POU class 5 homeobox 1; SOX2, SRY-related
HMG-box 2; CDK, cyclin-dependent kinase; VIRMA, Vir-like M6A
methyltransferase associated; ACTA2, actin alpha 2; COL1A1, type I
collagen; FN1, fibronectin; HDAC, histone deacetylase; POLD4, DNA
Polymerase Delta 4, Accessory Subunit; TGF-β, transforming growth
factor beta; VIM, vimentin; XPC, XPC complex subunit, DNA damage
recognition and repair factor; NES, nestin; STMN2, stathmin-2;
REV7; reversionless 7; has-miR, Homo sapiens microRNA; ANXA1,
annexin A1; TAGLN, Transgelin; TEXT11, testis-expressed 11;
LINC003131, long intergenic non-coding RNA; PTTG1, pituitary
tumor-transforming gene 1; DAPT,
N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl
ester; MLN4924, pevonedistat; MG-132, proteasome inhibitor; PDE4,
phosphodiesterase 4; SENP1, SUMO specific peptidase 1; ILK,
integrin linked kinase; SNAIL, snail family transcriptional
repressor 1; TWIST1, Twist-related protein 1; NAE1, NEDD8
activating enzyme E1 subunit 1; HIF-1α, hypoxia inducible factor 1
Subunit Alpha ; ZEB2, zinc finger E-box binding homeobox 2; HMOX1,
heme oxygenase 1; NOTCH1, notch receptor 1.](/article_images/ijo/67/6/ijo-67-06-05811-g02.jpg)
